-0.000762324241910922 -0.00127054040318475 -0.00152464848382172 0.00389632390310019 0.00711502625783503 0.00423513467728274 0.00423513467728274 0.00423513467728274
Sign Up Today X
Thanks for submitting the form.
Stockreport

BioMarin: Amicus Buyout Sparks My Enthusiasm [Seeking Alpha]

BioMarin Pharmaceutical Inc. (BMRN)  More Company Research Source: Seeking Alpha
Last biomarin pharmaceutical inc. earnings: 4/29 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.biomarin.com
It has an extensive portfolio of enzyme replacement therapies, including Palynziq, Vimizim, and Brineura. For example, sales of Brineura, approved for CLN2 disease, reached $48 million in Q3, up 29.7% year-on-year. And in my opinion, the acquisition of Amicus for $4.8 billion significantly strengthened and rejuvenated BioMarin's ERTs portfolio. As a result, I'm initiating coverage of BioMarin with a 'Buy' rating. Martin Barraud/OJO Images via Getty Images BioMarin Pharmaceutical ( BMRN ) is my favorite in the rare disease therapeutics market thanks to Voxzogo, Palynziq, and Brineura. But despite the solid performance of this 'trio,' its shares have fallen 35.5% over the past year and a half. In my This article was written by Analyst's Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinion [Read more]
IMPACT SNAPSHOT EVENT TIME: BMRN
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Opt-in for
BMRN alerts
from News Quantified
BMRN
NEWS
BMRN
Earnings
BMRN
Analyst Actions
BMRN
SEC Filings
Stockreport

BioMarin: Amicus Buyout Sparks My Enthusiasm [Seeking Alpha]

BioMarin Pharmaceutical Inc.  (BMRN) 
More Company Research Source: Seeking Alpha
Last biomarin pharmaceutical inc. earnings: 4/29 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.biomarin.com
It has an extensive portfolio of enzyme replacement therapies, including Palynziq, Vimizim, and Brineura. For example, sales of Brineura, approved for CLN2 disease, reached $48 million in Q3, up 29.7% year-on-year. And in my opinion, the acquisition of Amicus for $4.8 billion significantly strengthened and rejuvenated BioMarin's ERTs portfolio. As a result, I'm initiating coverage of BioMarin with a 'Buy' rating. Martin Barraud/OJO Images via Getty Images BioMarin Pharmaceutical ( BMRN ) is my favorite in the rare disease therapeutics market thanks to Voxzogo, Palynziq, and Brineura. But despite the solid performance of this 'trio,' its shares have fallen 35.5% over the past year and a half. In my This article was written by Analyst's Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinion [Read more]
IMPACT SNAPSHOT
EVENT TIME:
BMRN
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Don't Miss Out On The Next BIG Stock Move
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS